Research peptide · Immune research
LL-37
A synthetic 37-residue cationic peptide matching the C-terminal fragment of the cathelicidin precursor protein encoded by the CAMP gene. It is one of the most studied members of the cathelicidin family in laboratory work.
- Compound type
- Research peptide
- Research area
- Immune
- Formula
- C205H340N60O53
- Average mass
- 4,493.263 Da
- Monoisotopic mass
- 4,490.5754 Da
- Length
- 37 residues
- PubChem
- CID 16198951
What it is
LL-37 is a synthetic peptide of 37 amino acids, sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES. Its molecular formula is C205H340N60O53 and its average molecular weight is 4493 g/mol. It carries CAS number 154947-66-7 and PubChem CID 16198951, and appears in the literature as LL37, cathelicidin LL-37, CAP-18 and ropocamptide.
The name is descriptive rather than coded: the chain begins with two leucines and runs 37 residues. The sequence corresponds to the C-terminal portion of hCAP18, the single cathelicidin precursor protein encoded by the CAMP gene, from which the mature peptide is released by proteolytic processing. The material supplied here is made by solid-phase synthesis, without the cathelin prodomain.
Discovery and origin
Cathelicidins were defined as a protein family in the early 1990s on the basis of a conserved N-terminal cathelin domain attached to a variable C-terminal segment. Members had been described in several mammals, and the single member encoded in the human genome, hCAP18, was characterized over the same period; the 37-residue C-terminal peptide released from it was named LL-37 and has since become the reference antimicrobial peptide for the family 1.
A review of the field summarizes the family as an unusual class of peptides whose members show multiple activities in assay systems beyond antibacterial behavior, including antifungal and antiviral activity, and chemotactic and immunomodulatory effects in cell culture 1.
Structure and chemistry
LL-37 is strongly cationic and strongly amphipathic, and those two properties govern nearly everything about handling it. The sequence carries six lysines and five arginines against five acidic residues, giving a large net positive charge at neutral pH. In membrane-mimetic environments the chain folds into an amphipathic alpha helix with basic and hydrophobic residues on opposite faces, the structural basis for its interaction with anionic lipid surfaces.
At 4493 g/mol it is one of the larger peptides in this compendium. Its conformation in solution is condition-dependent: ionic strength, pH, concentration and the presence of anionic surfactants or lipids all shift the balance between disordered monomer and helical or oligomeric states, which is why published biophysical work on this peptide is careful to specify buffer composition.
The sequence contains three phenylalanines but no tryptophan, tyrosine or cysteine, so there is no disulfide chemistry and only weak absorbance at 280 nm. Concentration is normally determined by peptide-bond absorbance at 214 nm, by amino acid analysis, or by a colorimetric protein assay. The strong positive charge also makes the peptide prone to adsorption onto glass and some plastics in dilute aqueous handling.
How it is studied in the laboratory
Published laboratory work on LL-37 falls into three broad families of assay. The first is microbiology: susceptibility testing against bacterial and fungal cultures to determine minimum inhibitory concentrations, membrane permeabilization assays using dye uptake or leakage from liposomes, and biofilm assays 1. The second is biophysics: circular dichroism and related methods used to follow the disorder-to-helix transition in defined buffers, and model-membrane work pairing the peptide with vesicles of defined lipid composition.
The third family is cell culture. Reviewed work describes chemotactic assays and measurements of immune signaling in cultured cells 1. Reported activities depend strongly on medium composition, because serum components and physiological salt concentrations alter the peptide's behavior in the assay, so comparability between laboratories is itself a recurring methodological topic and published methods sections are explicit about salt, serum and surface materials.
Analytical notes
Identity is confirmed by liquid chromatography coupled to mass spectrometry. A peptide of this size produces a multiply charged envelope rather than a single dominant ion. On the average mass of 4493 g/mol, the expected ions include [M+4H]4+ near m/z 1124.26, [M+5H]5+ near m/z 899.61 and [M+6H]6+ near m/z 749.84; with eleven basic residues the envelope commonly extends to higher charge states, and deconvolution to the neutral mass is the more robust identity check. A monoisotopic calculation on 4490.58 shifts the series slightly, so the convention in use should be stated.
Purity is assessed by reversed-phase HPLC, usually with a shallow acetonitrile gradient in trifluoroacetic acid. Thirty-seven residues is long enough that deletion and truncation sequences are the dominant impurity class, and many differ from the full-length product by a single residue and elute very close to it, so resolution matters more here than for a short peptide. The methionine-free, cysteine-free composition removes the two most common oxidation artifacts, but the aspartate-glycine pair early in the sequence is a known isomerization-prone motif. Counter-ion content is worth quantifying here in particular: with eleven basic sites, a trifluoroacetate salt carries a substantial non-peptide mass fraction, so gravimetric concentration from powder weight overstates peptide content.
Storage and handling in the laboratory
As supplied, the material is a lyophilized white powder, soluble in water, stored at -20 degrees Celsius and protected from light and moisture. The lyophilized state is the stable one, and freeze-thaw cycling of solutions is the handling step most likely to cause loss, through aggregation and adsorption to container surfaces; low-binding polypropylene rather than glass is the common choice for dilute solutions. Vials should reach room temperature before opening so that moisture does not condense onto cold powder.
Open questions in the literature
The clearest gap is between assay conditions and anything more complex. Activities measured in low-salt buffer are frequently reduced in media approximating physiological ionic strength and in the presence of serum proteins, and how to interpret that difference remains contested. The oligomeric state under each assay condition is often unknown, which complicates comparison of potency values between studies. The breadth of activities attributed to the molecule also raises the question of how many follow from a single membrane-interaction mechanism 1.
Identity check
A mass-spectrometry result for LL-37 should show peaks near these values. A result more than about one unit away is worth a question to the testing lab. Salt forms such as acetate or TFA do not move these peaks, though they do mean less peptide in each milligram of powder.
| Ion | Expected m/z |
|---|---|
| [M+3H]3+ | 1497.87 |
| [M+4H]4+ | 1123.65 |
| [M+5H]5+ | 899.12 |
References
- Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology. 2012;280(1):22-35. doi:10.1016/j.cellimm.2012.11.009. Source
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.
